文献速递糖尿病

达格列净按基线血糖状态分层的疗效与安全性:DAPA-CKD 试验预设分析

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
PubMed 文献 · Diabetes Care · 2021-06-28

DAPA-CKD 试验预设分析比较了达格列净与安慰剂在慢性肾脏病患者中按基线血糖状态(正常血糖、糖尿病前期、2型糖尿病)的疗效与安全性。主要复合终点在三种血糖状态下获益一致(交互作用 P=0.19),正常血糖和糖尿病前期患者无严重低血糖或酮症酸中毒。达格列净独立于基线血糖状态安全降低肾脏和心血管事件。

要点

  • 达格列净降低主要肾脏复合终点独立于基线血糖状态。
  • 正常血糖和糖尿病前期患者使用达格列净无严重低血糖或酮症酸中毒。
  • 三种血糖状态间疗效无显著异质性(交互作用 P=0.19)。

核心结论

  • 达格列净独立于基线血糖状态安全降低肾脏和心血管事件。

研究设计与样本

  • DAPA-CKD 试验预设分析,纳入 eGFR 25-75 mL/min/1.73 m2 且 UACR 200-5,000 mg/g 的 CKD 患者共 4,304 例。
  • 按基线血糖状态分为正常血糖 738 例、糖尿病前期 660 例、2型糖尿病 2,906 例。
  • 主要复合终点为持续 eGFR 下降≥50%、终末期肾病或肾脏/心血管死亡。

主要发现

  • 主要终点风险比:正常血糖 HR 0.62(95% CI 0.39, 1.01),糖尿病前期 HR 0.37(0.21, 0.66),2型糖尿病 HR 0.64(0.52, 0.79)。
  • 主要终点交互作用 P=0.19,未发现任何结局存在效应修饰证据。
  • 正常血糖或糖尿病前期参与者中无严重低血糖或酮症酸中毒,不良事件相似。

临床怎么用

  • CKD 患者使用达格列净的肾脏和心血管获益不依赖于基线血糖状态。
  • 正常血糖或糖尿病前期的 CKD 患者使用达格列净未观察到严重低血糖或酮症酸中毒。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status. RESEARCH DESIGN AND METHODS: We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m2, and urinary albumin-to-creatinine ratio 200-5,000 mg/g. The primary composite end point was sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death. RESULTS: Of 4,304 participants, 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes. The effect of dapagliflozin on the primary outcome was consistent (P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]). We found no evidence for effect modification on any outcome. Adverse events were similar, with no major hypoglycemia or ketoacidosis in participants with normoglycemia or prediabetes. CONCLUSIONS: Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Persson F, Rossing P, Vart P, et al. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care. 2021. PMID: 34183431. doi:10.2337/dc21-0300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。